Benjamin Edwards Inc. Sells 19,815 Shares of Kenvue Inc. (NYSE:KVUE)

Benjamin Edwards Inc. lowered its holdings in Kenvue Inc. (NYSE:KVUE) by 34.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,396 shares of the company’s stock after selling 19,815 shares during the period. Benjamin Edwards Inc.’s holdings in Kenvue were worth $798,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Norges Bank acquired a new stake in Kenvue during the fourth quarter worth about $521,348,000. Franklin Resources Inc. boosted its position in shares of Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after acquiring an additional 16,269,721 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Kenvue by 12.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after acquiring an additional 10,682,003 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Kenvue by 3.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company’s stock valued at $5,249,665,000 after purchasing an additional 8,211,748 shares in the last quarter. Finally, Boston Partners lifted its stake in Kenvue by 36.9% during the fourth quarter. Boston Partners now owns 23,595,963 shares of the company’s stock worth $503,145,000 after purchasing an additional 6,366,097 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 1.7 %

Shares of KVUE opened at $24.47 on Friday. The stock’s 50-day moving average price is $23.13 and its two-hundred day moving average price is $22.56. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17. The company has a market capitalization of $46.95 billion, a PE ratio of 46.17, a PEG ratio of 2.62 and a beta of 1.02. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The business had revenue of $3.74 billion for the quarter, compared to analysts’ expectations of $3.69 billion. During the same period in the prior year, the business posted $0.28 earnings per share. The firm’s revenue was down 3.9% on a year-over-year basis. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue’s dividend payout ratio is presently 154.72%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. UBS Group boosted their price target on Kenvue from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Friday. Citigroup boosted their target price on Kenvue from $22.00 to $24.50 and gave the stock a “neutral” rating in a research note on Friday. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Finally, Barclays decreased their target price on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Monday, April 14th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average price target of $25.25.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.